What’s the current market cap for Healthpeak Properties stock?

Healthpeak Properties (DOC) has a market cap of $14bn as of June 15, 2026.

What is the P/E ratio for Healthpeak Properties stock?

The price to earnings (P/E) ratio for Healthpeak Properties (DOC) stock is 64.88 as of June 15, 2026.

Does Healthpeak Properties stock pay dividends?

Yes, the Healthpeak Properties (DOC) stock pays dividends to shareholders. As of June 15, 2026, the dividend rate is $1.22004 and the yield is 5.9%. Healthpeak Properties has a payout ratio of 381.55% on a trailing twelve-month basis.

When is the next Healthpeak Properties dividend payment date?

The next Healthpeak Properties (DOC) dividend payment is scheduled for June 26, 2026.

What is the beta indicator for Healthpeak Properties?

Healthpeak Properties (DOC) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Healthpeak Properties stock | $DOC Share Price

13:30

15:10

16:45

18:25

20:00

About Healthpeak Properties

Healthpeak owns a diversified healthcare portfolio of approximately 700 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.

Ticker

$DOC

Sector

Real Estate

Primary listing

NYSE

Employees

411

Headquarters

Denver, United States

Website

www.healthpeak.com

DOC Metrics

BasicAdvanced

$14bn

64.88

$0.32

0.98

$1.22

5.90%

What the Analysts think about DOC

Majority rating from 19 analysts.

Buy

Bulls say / Bears say

Healthpeak delivered Q1 2026 revenue of $752.95 million, up 7.1% year-over-year, and EPS of $0.45, exceeding the $0.43 consensus and fueling an 18% stock surge on May 5, 2026.

Healthpeak raised its full-year 2026 FFO as adjusted guidance to $1.71–$1.75 per share, up $0.01 at the midpoint, reflecting management’s confidence in resilient cash flow.

Janus Living’s IPO was completed at the top end of its valuation range in March 2026, raising about $880 million in net proceeds and leaving Healthpeak with an 81.6% stake that positions it for accretive growth in senior housing.

Challenges persist in the lab portfolio, as lab same-store cash NOI fell 7.2% in Q1 2026 and management expects another 5–10% NOI decline in the lab division for all of 2026.

Net debt to adjusted EBITDA stands at 5.4x, and with interest expense set to rise by $20 million and interest coverage at just 1.6x, refinancing risks are elevated in the current high-rate environment.

Management maintained its full-year same-store cash NOI growth guidance of –1.0% to +1.0%, highlighting weak underlying growth across the core healthcare portfolio.

Data summarised monthly by Lightyear AI. Last updated on 31 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DOC

Capital at risk

Market open

Upcoming events